For prescribing information, click here

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

Decapeptyl® (triptorelin) SR 3 mg, Decapeptyl® (triptorelin) 3-month 11.25 mg and Decapeptyl® (triptorelin) 6-month 22.5 mg therapeutic indications.

Decapeptyl® (triptorelin) SR and Decapeptyl® (triptorelin) 3-month are indicated for:

  • Management of advanced prostatic carcinoma.

Decapeptyl® (triptorelin) 6-month is indicated for:

  • Treatment of locally advanced or metastatic.
  • Hormone-dependent prostate cancer.

What is Ipsen’s Congress360Peer at ESTRO 2026?

The program content was focused on prostate cancer and was peer‑led by an expert international faculty to ensure distilled and clinically relevant updates from a trusted source. Read on for an overview of the Congress360Peer program and the selected title highlights from our faculty.

Selected ESTRO 2026 titles of interest from our faculty

  • Early toxicity of elective nodal RT for oligorecurrent pelvic/paraaortic nodes in prostate cancer: A randomized Phase III trial OLIGOPELVIS‑2/GETUG P12
  • Updated clinical outcomes from the RADIOSA randomized Phase II trial
  • Acute toxicity in PACE‑NODES: A randomized trial of 5 fraction (f) prostate stereotactic body radiotherapy (SBRT) vs 5f prostate and pelvic nodal SBRT
  • Salvage hypofractionated accelerated versus standard radiotherapy for biochemical recurrence after radical prostatectomy (SHARE): A Phase III trial
  • PERSIAN TRIAL (NCT03449719): A randomized Phase II trial testing apalutamide and SBRT for hormone‑sensitive prostate cancer

Introducing our faculty for ESTRO 2026

Dr. Lopez Campos, Hospital Universitario Ramón y Cajal, Spain

Dr. Lopez Campos is a well‑known radio‑oncologist, with extensive experience in genitourinary cancers, including prostate cancer. He is widely published and has participated in many national and international clinical trials. He has spoken at several congresses and is a member of the Board of Directors of the IRAD.

Dr. Lopez Campos, Hospital Universitario Ramón y Cajal, Spain

Dr. Marvaso, Istituto Europeo di Oncologia, Italy

Dr. Marvaso is a radio‑oncologist with a specialization in prostate cancer. She is a research fellow at the University of Milan, whose research focuses on the use of radiotherapy in the management of cancer patients, as well as on the technological and biological issues of high‑precision radiotherapy. She is an active member of AIRO, serves on the Urological AIRO committee, and is also a member of both SIUrO and the ESTRO committee.

Dr. Marvaso, Istituto Europeo di Oncologia, Italy

Learn more about Ipsen’s Congress360Peer reviews by clicking the links below

Prostate Cancer Highlights from ESTRO 2026

Prostate Cancer Highlights from ESTRO 2026

Click below to learn more about Ipsen's Congress360Peer highlights in prostate cancer from ESTRO 2026, curated by our expert faculty to provide you with key information from the congress.
Learn More
Watch the Ipsen's Congress360Peer Faculty Discuss Key Takeaways from ESTRO 2026

Watch the Ipsen's Congress360Peer Faculty Discuss Key Takeaways from ESTRO 2026

Watch the Ipsen's Congress360Peer faculty discuss the key highlights in prostate cancer from ESTRO 2026. Hear discussions on key data including pelvic treatment and findings from the RADIOSA trial, and their potential to impact daily clinical practice.
Watch now

Abbreviations

AIRO, Italian Society of Radiotherapy and Clinical Oncology; ESTRO, European Society for Radiotherapy and Oncology; IRAD, Institute for Research in Radiation Oncology; RT, radiotherapy; SBRT, stereotactic body radiotherapy; SmPC, Summary of Product Characteristics; SIUrO, Italian Society of Uro‑Oncology.

Resources

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.